Telomir Pharmaceuticals, Inc. - TELO STOCK NEWS

Telomir Pharmaceuticals (NASDAQ:TELO) has appointed Dr. Itzchak Angel as Chief Scientific Advisor to expedite the development of Telomir-1, a novel small molecule designed to lengthen telomeres. Dr. Angel, former Head of Pharmacology at Synthelabo (now Sanofi-Aventis), brings over 40 years of expertise in drug development. Telomir is pursuing both Investigational New Drug (IND) and Investigational New Animal Drug (INAD) applications for Telomir-1.

The company is exploring Telomir-1's potential for treating rare aging-related diseases like progeria, which could qualify for orphan drug designation. Dr. Angel will focus on unveiling the molecular mechanisms of Telomir-1, including its effects on ion-chelation, cytokine modification, and intracellular pathways. This appointment aims to accelerate Telomir's progress in longevity science and the treatment of age-related conditions in both humans and animals.

Telomir Pharmaceuticals (NASDAQ:TELO) has been featured in a local ABC exclusive highlighting promising age reversal outcomes in two senior dogs using their novel small molecule, Telomir-1. The compassionate use program, observed by Dr. Michael Roizen, showed remarkable improvements in the dogs' health and vitality. Zeus, a 12-year-old German Shepherd, experienced complete remission of terminal cancer, while Benson, a 12-year-old Newfoundland with severe arthritis, regained mobility.

Erez Aminov, Telomir's new Chairman CEO, emphasized the company's commitment to advancing Telomir-1's research and accelerating its path to market. Dr. Roizen expressed excitement about Telomir-1's potential to promote cell regeneration and reverse aspects of aging by lengthening telomeres. The company aims to progress towards human trials for specific indications.

Telomir Pharmaceuticals (Nasdaq: TELO) announced the passing of its Chairman and CEO, Dr. Christopher Chapman. The company's Board of Directors has appointed Erez Aminov as the new CEO and Chairman. Aminov is currently the CEO and Chairman of MIRA Pharmaceuticals (Nasdaq: MIRA).

In addition, Telomir announced changes to its Board of Directors. Three directors have voluntarily resigned, and three new directors have been appointed: Dr. Matthew P. Del Giudice, Mr. Ned MacPherson, and Matthew Pratt Whalen, CPA. Dr. Craig Eagle and Michael Jerman will remain on the board.

Telomir Pharmaceuticals is a pre-clinical-stage company focused on developing Telomir-1, a drug candidate aimed at promoting longevity in humans and dogs through the treatment of age-related conditions.

Telomir Pharmaceuticals (Nasdaq: TELO), a pre-clinical-stage pharmaceutical company, has been added to the Russell 3000 and Russell Microcap Indexes as of July 1, 2024.

This inclusion follows the annual Russell indexes reconstitution, which ranks the 4,000 largest US stocks by market capitalization. Membership in these indexes signifies automatic inclusion in either the Russell 1000 or Russell 2000 indexes, impacting index funds and active investment strategies.

FTSE Russell manages these indexes, which benchmark approximately $10.5 trillion in assets. Telomir's CEO, Dr. Chris Chapman, highlighted this milestone as evidence of the company's progress since its IPO in February and its commitment to advancing Telomir-1, a potential treatment for age-related conditions.

Telomir Pharmaceuticals (Nasdaq: TELO), a pre-clinical-stage pharmaceutical company, announced the participation of its scientific advisor, Dr. Adam Kaplin, in the Drug Information Association (DIA) 2024 Global Annual Meeting on June 17, 2024. The event, being the largest global gathering for professionals in pharmaceuticals, biotechnology, and medical devices, will feature Dr. Kaplin in a panel discussion on generative AI in clinical trials. He will discuss how AI-powered data modeling can significantly reduce time and cost in therapeutic studies while maintaining high patient safety standards. This approach has the potential to expedite drug dosing, trial performance, and patient safety by up to 90%.

Telomir Pharmaceuticals (Nasdaq: TELO) announced significant milestones for its lead product candidate, Telomir-1. The Company began a pivotal study on May 28, 2024, to evaluate the safety and efficacy of Telomir-1 in geriatric laboratory Beagle dogs over 63 days. The initial dosing was well-tolerated by all animals, aiming to treat age-related conditions like gait weakness and joint damage. Additionally, Telomir is treating a 12-year-old German Shepherd named Zeus with Telomir-1, gathering real-world data for future research and regulatory efforts. These studies are key steps towards developing treatments for both veterinary and human age-related diseases.

Telomir Pharmaceuticals presents promising pre-clinical data on Telomir-1 at a National Press Club event, showcasing a 40% increase in telomerase activity and lengthening of telomeres in human cells. The company plans to initiate human clinical trials for osteoarthritis and veterinary trials in 2025 after pre-clinical studies in 2024.

Telomir Pharmaceuticals, Inc. announces promising pre-clinical research on Telomir-1, a novel small molecule that elongates telomere caps to potentially address age-related conditions. The company will present research findings at the National Press Club in Washington, DC. Telomir-1 aims to stimulate stem cell renewal and treat age-related conditions like osteoarthritis.

Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) and Argenta to conduct a study on the efficacy of Telomir-1 in treating osteoarthritis in canines. The study aims to evaluate the potential of Telomir-1 to mitigate the clinical signs of osteoarthritis and other age-related diseases, with the possibility of extending its use to humans. Telomir-1 could offer a disease-modifying therapy for canines, enhancing their quality of life and mobility.